MA32981B1 - Regime posologique pour un agoniste du recepteur s1p - Google Patents
Regime posologique pour un agoniste du recepteur s1pInfo
- Publication number
- MA32981B1 MA32981B1 MA34034A MA34034A MA32981B1 MA 32981 B1 MA32981 B1 MA 32981B1 MA 34034 A MA34034 A MA 34034A MA 34034 A MA34034 A MA 34034A MA 32981 B1 MA32981 B1 MA 32981B1
- Authority
- MA
- Morocco
- Prior art keywords
- receptor agonist
- dosing system
- daily dose
- receptor
- analogues
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000003607 modifier Substances 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur des modulateurs ou agonistes du récepteur S1P qui sont administrés selon un régime posologique, dans lequel durant les jours initiaux de traitement, le dosage quotidien est inférieur au dosage quotidien standard.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967208P | 2008-12-22 | 2008-12-22 | |
US21853009P | 2009-06-19 | 2009-06-19 | |
US24671509P | 2009-09-29 | 2009-09-29 | |
PCT/US2009/068888 WO2010075239A1 (fr) | 2008-12-22 | 2009-12-21 | Régime posologique pour un agoniste du récepteur s1p |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32981B1 true MA32981B1 (fr) | 2012-01-02 |
Family
ID=41667217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34034A MA32981B1 (fr) | 2008-12-22 | 2009-12-21 | Regime posologique pour un agoniste du recepteur s1p |
Country Status (41)
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY177360A (en) | 2008-03-17 | 2020-09-14 | Actelion Pharmaceuticals Ltd | Dosing regimen for aselective s1p1 receptor agonist |
RS59857B1 (sr) | 2008-12-22 | 2020-02-28 | Novartis Ag | Režim doziranja agonista s1p receptora |
US20120264719A1 (en) | 2009-09-29 | 2012-10-18 | Craig Boulton | Dosage regimen of an s1p receptor modulator |
US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス |
JP2013525469A (ja) * | 2010-05-06 | 2013-06-20 | ノバルティス アーゲー | ジアリールスルフィド誘導体の投与レジメン |
EP2455080A1 (fr) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques |
FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
MX357304B (es) | 2011-01-07 | 2018-07-04 | Novartis Ag | Formulaciones inmunosupresoras. |
EP2675893B1 (fr) | 2011-02-18 | 2019-01-09 | The Scripps Research Institute | Différenciation dirigée de cellules précurseurs d'oligodendrocytes vers un destin cellulaire myélinisant |
JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
WO2012162392A1 (fr) * | 2011-05-23 | 2012-11-29 | Timothy Hla | Matériaux protecteurs de l'endothélium et procédés d'utilisation |
TW201320994A (zh) * | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
LT2885266T (lt) | 2012-08-17 | 2020-07-10 | Actelion Pharmaceuticals Ltd | (2z,5z)-5-(3-chlor-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ono gamybos būdas ir šiame procese naudojamas tarpinis junginys |
WO2014138502A1 (fr) * | 2013-03-06 | 2014-09-12 | Acorda Therapeutics, Inc. | Dosage thérapeutique d'une neuréguline ou d'un fragment associé pour le traitement ou la prophylaxie de l'insuffisance cardiaque |
JP6401257B2 (ja) | 2013-10-11 | 2018-10-10 | テイコク ファーマ ユーエスエー インコーポレーテッド | 局所用スフィンゴシン−1−リン酸受容体アゴニスト製剤及びその使用方法 |
US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
MX2016013245A (es) * | 2014-04-10 | 2017-01-16 | Novartis Ag | Regimen de dosificacion de liberacion inmediata de moduladores s1p. |
DK3256125T3 (da) | 2014-12-11 | 2022-03-21 | Actelion Pharmaceuticals Ltd | Doseringsregimen for ponesimod, en selektiv s1p1-receptoragonist |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CA2973540A1 (fr) | 2015-02-26 | 2016-09-01 | Novartis Ag | Traitement de maladie auto-immune chez un patient recevant en outre un betabloquant |
CA3002551A1 (fr) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1 |
EP3582814B1 (fr) | 2017-02-16 | 2024-05-01 | Arena Pharmaceuticals, Inc. | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
WO2021084068A1 (fr) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combinaison d'un antagoniste de cxcr7 avec un modulateur du récepteur s1p1 |
WO2021158838A1 (fr) | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Régime posologique d'un modulateur du récepteur s1p |
WO2021158848A1 (fr) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Régime posologique d'un agoniste du récepteur s1p |
CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2126658T3 (es) | 1992-10-21 | 1999-04-01 | Yoshitomi Pharmaceutical | Compuesto de 2-amino-1,3-propanodiol e inmunosupresor. |
JP2004507552A (ja) | 2000-08-31 | 2004-03-11 | メルク エンド カムパニー インコーポレーテッド | 免疫調節剤としてのリン酸誘導体 |
DK1505959T3 (da) | 2002-05-16 | 2009-02-23 | Novartis Ag | Anvendelse af EDG-receptorbindingsmidler ved cancer |
EP1663188B1 (fr) * | 2003-09-12 | 2016-08-10 | Newron Sweden AB | Traitement de maladies ou de lesions du systeme nerveux avec le fty720 |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
AU2005309378B2 (en) * | 2004-11-29 | 2010-02-11 | Novartis Ag | Dosage regimen of an S1P receptor agonist |
EP1688141A1 (fr) * | 2005-01-31 | 2006-08-09 | elbion AG | Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable |
WO2006085316A2 (fr) * | 2005-02-10 | 2006-08-17 | G.I. View Ltd. | Techniques de deplacement d'un outil gastro-intestinal equipe d'un element de guidage |
HUE027696T2 (en) | 2007-10-12 | 2016-10-28 | Novartis Ag | Preparations containing sphingosine-1-phosphate (S1P) receptor modulators |
MY177360A (en) * | 2008-03-17 | 2020-09-14 | Actelion Pharmaceuticals Ltd | Dosing regimen for aselective s1p1 receptor agonist |
KR20160131126A (ko) * | 2008-06-20 | 2016-11-15 | 노파르티스 아게 | 다발성 경화증을 치료하기 위한 소아용 조성물 |
RS59857B1 (sr) | 2008-12-22 | 2020-02-28 | Novartis Ag | Režim doziranja agonista s1p receptora |
IL294658A (en) | 2008-12-22 | 2022-09-01 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
-
2009
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/fr active Active
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/fr active Application Filing
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/fr active Pending
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/fr not_active Withdrawn
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/fr unknown
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/fr unknown
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active IP Right Grant
- 2009-12-21 EP EP22187007.4A patent/EP4098256A1/fr active Pending
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/fr not_active Revoked
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 CA CA2747802A patent/CA2747802C/fr active Active
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/fr active Active
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/fr not_active Withdrawn
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
-
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
-
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
-
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
-
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-06 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
-
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
-
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-17 LU LU00183C patent/LUC00183I2/fr unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
-
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en active Pending
-
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32981B1 (fr) | Regime posologique pour un agoniste du recepteur s1p | |
MA32907B1 (fr) | Régime posologique d'un agoniste du récepteur s1p | |
EA201001135A1 (ru) | Интратекальное лечение невропатической боли агонистами ar | |
EA200870424A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
BR112013027554A2 (pt) | "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios" | |
EA201391087A1 (ru) | Оральные лекарственные формы препарата тазоцитиниба с модифицированным высвобождением | |
MX2010009853A (es) | Regimen de dosificacion para un agonista de receptor selectivo de s1p1. | |
DOP2012000238A (es) | Compuestos de para la inhibición de inmunoproteasomas | |
MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
MX2019006900A (es) | Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno. | |
EA200970512A1 (ru) | Лечение по поводу множественной миеломы | |
PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
EA202091676A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
PH12015502282A1 (en) | Alpha-2 adrenoceptor and sigma receptor ligand combinations | |
GEP20156231B (en) | Agomelatine hydrochloride hydrate and preparation there of | |
BR112014011223A2 (pt) | método de tratar uma doença proliferativa | |
EA201490210A1 (ru) | Блокаторы потенциалзависимых натриевых каналов | |
MX2008011020A (es) | Compuestos de receptor sigma. | |
MX338595B (es) | Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. | |
MX2013006185A (es) | Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos. | |
UA112448C2 (uk) | Композиція і спосіб лікування аутоімунного захворювання | |
WO2012051213A3 (fr) | Analogues 5,6,5-tricycliques thérapeutiques |